Breaking Finance News

Keryx Biopharmaceuticals (NASDAQ:KERX) target price bumped up to $5.93, released a ratings update earlier today by Vetr Inc.

Yesterday Keryx Biopharmaceuticals (NASDAQ:KERX) traded -8.49% lower at $4.97. The company’s 50-day moving average is $4.84 and its 200-day moving average is $5.46. The last closing price is down -9.22% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 2,699,019 shares of the stock traded hands, up from an average trading volume of 1,733,650

Vetr Inc. upped the price target of Keryx Biopharmaceuticals (NASDAQ:KERX) to $5.93 indicating a possible upside of 0.19%.

Performance Chart

Keryx Biopharmaceuticals (NASDAQ:KERX)

With a total market value of $0, Keryx Biopharmaceuticals has with a one year low of $2.80 and a one year high of $7.80 .

A total of 10 equity analysts have released a ratings update on KERX. Four equity analysts rating the company a strong buy, three equity analysts rating the company a buy, three equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally two equity analysts rating the company a sell with a one year target of $7.63.

Brief Synopsis About Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company's product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough. The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *